Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HuMax IL8 - Bristol-Myers Squibb/Genmab

Next Previous
Drug Profile

HuMax IL8 - Bristol-Myers Squibb/Genmab

Alternative Names: anti-IL8 mAb - Bristol-Myers Squibb/Genmab; BMS-986253; HuMax-IL8; HuMax-Inflam; HuMax®-IL8; MDX 018

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab; Medarex
  • Developer Bristol-Myers Squibb; Columbia University; Genmab; Icahn School of Medicine at Mount Sinai; Medarex; NYU Langone Health; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID 2019 infections; Liver cancer; Non-small cell lung cancer; Squamous cell cancer
  • Phase I/II Prostate cancer; Solid tumours
  • Discontinued Autoimmune disorders; Glioblastoma; Palmoplantar pustulosis

Most Recent Events

  • 01 Jul 2022 National Cancer Institute plans a phase I/II trial for Myelodysplastic syndromes (Monotherapy, Combination therapy) in USA (IV, Infusion) in July 2022 (NCT05148234)
  • 03 Jun 2022 Interim efficacy and adverse events data from a phase Ib/II MAGIC-8 trial in prostate cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
  • 07 Dec 2021 Columbia University and Bristol-Myers Squibb terminates a phase-II trials in COVID-2019 infections in cancer patients (Treatment-experienced) in USA (IV) (NCT04347226)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top